Literature DB >> 24074875

National estimates of the burden of inflammatory bowel disease among racial and ethnic groups in the United States.

Geoffrey C Nguyen1, Christopher A Chong2, Rachel Y Chong2.   

Abstract

BACKGROUND: The epidemiology of inflammatory bowel disease (IBD) is poorly characterized in minorities in the U.S. We sought to enumerate the burden of IBD among racial and ethnic groups using national-level data.
METHODS: Data from the National Health Interview Survey was used to calculate prevalence and incidence of IBD among adults (≥ 18 years) in 1999. The Nationwide Inpatient Sample was queried to ascertain rates of IBD-related hospitalizations and the Underlying Cause of Death Database was accessed to quantify IBD-related mortality.
RESULTS: An estimated 1,810,773 adult Americans were affected by IBD yielding a prevalence of 908/100,000, which was higher in Non-Hispanic Whites (1099/100,000) compared with Non-Hispanic Blacks (324/100,000), Hispanics (383/100,000), and non-Hispanic Other (314/100,000). Relative to Non-Hispanic Whites, the odds ratios for having a diagnosis of IBD associated with being Non-Hispanic Black, Hispanic, and Other Non-Hispanic race after adjusting for age, sex, and geographic region were 0.33 (95% CI: 0.19 - 0.57), 0.45 (95% CI: 0.26 - 0.77), and 0.34 (95% CI: 0.12 - 0.93), respectively. IBD incidence was similarly lower in Non-Hispanic Blacks (24.9/100,000) and Hispanics (9.9/100,000) compared to Non-Hispanic Whites (70.2/100,000). The ratio of IBD hospitalizations to prevalence was disproportionately higher among Non-Hispanic Blacks (7.3%) compared with Non-Hispanic Whites (3.0%) and Hispanics (2.7%). Similarly, the ratio of IBD-related mortality was greater in Non-Hispanic Blacks (0.061%) compared to Non-Hispanic Whites (0.036%) and Hispanics (0.026%).
CONCLUSIONS: IBD disease burden is lower in ethnic minorities compared to Non-Hispanic Whites. However, IBD-related hospitalizations and deaths seem disproportionately high in Non-Hispanic Blacks.
© 2013.

Entities:  

Keywords:  Crohn's disease; Hospitalization; Inflammatory bowel disease; Prevalence; Race; Ulcerative colitis

Mesh:

Year:  2013        PMID: 24074875     DOI: 10.1016/j.crohns.2013.09.001

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  54 in total

1.  Predicting Costs of Care for Patients With Inflammatory Bowel Diseases.

Authors:  Benjamin Click; David G Binion; Alyce M Anderson
Journal:  Clin Gastroenterol Hepatol       Date:  2016-12-03       Impact factor: 11.382

2.  Racial disparities in readmission, complications, and procedures in children with Crohn's disease.

Authors:  Jennifer L Dotson; Michael D Kappelman; Deena J Chisolm; Wallace V Crandall
Journal:  Inflamm Bowel Dis       Date:  2015-04       Impact factor: 5.325

Review 3.  Hispanic Americans and Non-Hispanic White Americans Have a Similar Inflammatory Bowel Disease Phenotype: A Systematic Review with Meta-Analysis.

Authors:  Danny J Avalos; Antonio Mendoza-Ladd; Marc J Zuckerman; Mohammad Bashashati; Andres Alvarado; Alok Dwivedi; Oriana M Damas
Journal:  Dig Dis Sci       Date:  2018-03-29       Impact factor: 3.199

Review 4.  Possible mechanisms of action of mushroom-derived glucans on inflammatory bowel disease and associated cancer.

Authors:  Betty Schwartz; Yitzhak Hadar
Journal:  Ann Transl Med       Date:  2014-02

5.  Contraceptive method selection by women with inflammatory bowel diseases: a cross-sectional survey.

Authors:  Lori M Gawron; Andrew J Gawron; Amanda Kasper; Cassing Hammond; Laurie Keefer
Journal:  Contraception       Date:  2014-01-07       Impact factor: 3.375

6.  Lack of Difference in Treatment Patterns and Clinical Outcomes Between Black and White Patients With Inflammatory Bowel Disease.

Authors:  Edward L Barnes; Bharati Kochar; Millie D Long; Joel Pekow; Ashwin Ananthakrishnan; Adjoa Anyane-Yeboa; Christopher Martin; Joseph Galanko; Hans H Herfarth; Michael D Kappelman; Robert S Sandler
Journal:  Inflamm Bowel Dis       Date:  2018-11-29       Impact factor: 5.325

7.  High Incidence of Serologic Markers of Inflammatory Bowel Disease in Asymptomatic Patients with Glycogen Storage Disease Type Ia.

Authors:  Nicole T Lawrence; Tayoot Chengsupanimit; Laurie M Brown; David A Weinstein
Journal:  JIMD Rep       Date:  2015-06-21

8.  Demographic and Clinical Predictors of High Healthcare Use in Patients with Inflammatory Bowel Disease.

Authors:  Benjamin Click; Claudia Ramos Rivers; Ioannis E Koutroubakis; Dmitriy Babichenko; Alyce M Anderson; Jana G Hashash; Michael A Dunn; Marc Schwartz; Jason Swoger; Leonard Baidoo; Arthur Barrie; Miguel Regueiro; David G Binion
Journal:  Inflamm Bowel Dis       Date:  2016-06       Impact factor: 5.325

9.  Increased Prevalence of Inflammatory Bowel Disease in Patients with Mutations in Genes Encoding the Receptor Subunits for TGFβ.

Authors:  Anthony L Guerrerio; Pamela A Frischmeyer-Guerrerio; Chengrui Huang; Yuqiong Wu; Talin Haritunians; Dermot P B McGovern; Gretchen L MacCarrick; Steven R Brant; Harry C Dietz
Journal:  Inflamm Bowel Dis       Date:  2016-09       Impact factor: 5.325

10.  Risk Factors for Rehospitalization Within 90 Days in Patients with Inflammatory Bowel Disease.

Authors:  Jessica R Allegretti; Lawrence Borges; Matthew Lucci; Matthew Chang; Bonnie Cao; Emily Collins; Brian Vogel; Emily Arthur; Danielle Emmons; Joshua R Korzenik
Journal:  Inflamm Bowel Dis       Date:  2015-11       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.